医学
杜瓦卢马布
阶段(地层学)
肿瘤科
肺癌
合并(业务)
内科学
癌症
重症监护医学
免疫疗法
无容量
古生物学
会计
业务
生物
作者
Veronica Crespi,Marco Donatello Delcuratolo,Gabriele Minuti,Michele Montrone,Sara Pilotto,Elisa Roca,Giulio Metro,Alessandro Leonetti,Giacomo Pelizzari,Carlo Genova,Emanuela Olmetto,Diego Cortinovis,Alessandro Russo,Giulia Pasello,Alessandra Bulotta,Francesco Grossi,Roberta Buosi,Alessandro Del Conte,Claudio Sini,Carlo Greco
出处
期刊:Lung Cancer
[Elsevier BV]
日期:2025-05-03
卷期号:204: 108576-108576
被引量:2
标识
DOI:10.1016/j.lungcan.2025.108576
摘要
Platinum-based chemotherapy was the predominant treatment after durvalumab consolidation. Immunotherapy rechallenge was associated with the best survival outcome in selected cases, warranting further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI